A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT06937203
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT06937203
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, New Zealand
- Registry status
- Recruiting
Technical summary
Registry record NCT06937203. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-09 (actual); primary completion 2027-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- Condition
- Obesity
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- ARO-ALK7
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06937203- Content hash
1a2b747c415262f04bc7d91d757068fd89e0c2b19f239804e0959aff2436b080